A one-off procedure on the small intestine may help people hold on to more of the weight they lose with tirzepatide, a medicine used to treat obesity. In six-month results reported by Fractyl Health, people who received the company’s Revita procedure retained about 80% of their earlier weight loss, compared with 67% among those given a simulated procedure. Both groups regained some weight. U.S. Securities and Exchange Commission (source, opens in new tab)
U.S. Securities and Exchange CommissionFractyl Health’s Revita Meets Six-Month Co-Primary Endpoint in REMAIN-1 Pivotal StudyOpen source (opens in new tab)
Revita treats the lining of the duodenum, the first part of the small intestine. It is performed through an endoscope, a flexible tube used to reach inside the digestive tract. The trial is testing whether this treatment can help maintain weight loss after medication ends.
The findings are an interim company report from an ongoing trial, rather than a peer-reviewed publication. They suggest a benefit over six months, but do not yet establish whether it lasts longer.
The REMAIN-1 trial involved 308 adults with obesity who had lost at least 15% of their body weight with tirzepatide. After stopping the drug, they were randomly assigned to Revita or a sham procedure designed to resemble the treatment without delivering its active intervention. This helps researchers distinguish the treatment’s effect from differences related to participants’ expectations.
In the company’s analysis, the adjusted average weight regain at six months was 5.1% of body weight with Revita and 8.2% with the sham procedure. The gap was 3.1 percentage points and was statistically significant, meeting the trial’s planned six-month assessment. These percentages refer to body weight, not to the amount of weight participants had previously lost.
Fractyl reported no serious adverse events related to the device or procedure as of its safety review cutoff on 24 September 2026. That is an interim finding from a trial still under way. Revita remains investigational in the US.
A second main assessment remains unreported: whether participants maintain a loss of at least 5% of their original, pre-tirzepatide body weight at one year. That will provide a longer view of weight maintenance after stopping the drug. Whether Revita could match continued medication is a separate question this trial does not answer.
- U.S. Securities and Exchange Commission · Company releaseFractyl Health’s Revita Meets Six-Month Co-Primary Endpoint in REMAIN-1 Pivotal Studysec.gov · opens in new tab
